Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.77 |
| ▸ | FNTA | P49354 | 5/20 | 0.85 |
| ▸ | FNTB | P49356 | 5/20 | 0.85 |
| ▸ | TSHR | P16473 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | AR | P10275 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | SHBG | P04278 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403149 | 0.91 | FNTA (0.86) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone SCHEMBL4105700 | 0.89 | HSD17B10 (0.88) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL31249833 | 0.89 | FNTA (0.82) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL31249685 | 0.88 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| Hydrochloric Acid SCHEMBL31249712 | 0.88 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL2963066 | 0.88 | FNTA (0.81) | FNTAFNTBTSHRNR3C1KMT2A | |
| SCHEMBL21795267 | 0.87 | FNTA (0.82) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL9819556 | 0.87 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL9819561 | 0.87 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A | |
| Cortisone Acetate SCHEMBL4501 | 0.87 | FNTA (1.00) | FNTAFNTBTSHRNR3C1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| CN-106924738-B | The pharmaceutical composition for preventing lemostenosis | 北京大学第三医院 | 2019-12-03 | — | — | CN | claimed |
| CN-110123830-A | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare | 阿尔尼拉姆医药品有限公司 | 2019-08-16 | — | — | CN | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20220054417-A1 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | PURDUE RESEARCH FOUNDATION (US) | 2022-02-24 | — | — | US | disclosed |
| US-11185505-B2 | Delivery of agents to inflamed tissues using folate-targeted liposomes | PURDUE RESEARCH FOUNDATION (US) | 2021-11-30 | — | — | US | disclosed |
| CN-112225772-A | Synthesis process of hydrocortisone hemisuccinate | 安徽海洋药业有限公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20200297632-A1 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | PURDUE RESEARCH FOUNDATION (US) | 2020-09-24 | — | — | US | disclosed |
| US-20190298843-A1 | LIGAND IONOPHORE CONJUGATES | PURDUE RESEARCH FOUNDATION (US) | 2019-10-03 | — | — | US | disclosed |
| US-10406238-B2 | Ligand ionophore conjugates | PURDUE RESEARCH FOUNDATION (US) | 2019-09-10 | — | — | US | disclosed |
| CN-110178795-A | A kind of modeling method of macaque cold of insufficiency type syndrome model | 成都中医药大学 | 2019-08-30 | — | — | CN | disclosed |
| WO-2011150392-A1 | DELIVERY OF THERAPEUTIC AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20090226509-A1 | Composition for treatment of inflammatory disorders | ENCELADUS PHARMACEUTICALS B.V. (NL) | 2009-09-10 | — | — | US | disclosed |
| EP-1517675-B1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | ENCELADUS PHARMACEUTICALS B V (NL) | 2008-09-03 | — | — | EP | disclosed |
| US-20050152962-A1 | Liposomes composed of non-charged vesicle-forming lipids and water soluble corticosteroid for site-specific treatment of inflammatory disorders; for parenteral administration | ENCELADUS PHARMACEUTICALS B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1545994-A1 | INJECTABLE PHARMACEUTICAL SUSPENSION IN A TWO-CHAMBER VIAL | Pharmacia Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1517675-A1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | Universiteit Utrecht Holding B.V. (NL) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004018312-A1 | INJECTABLE PHARMACEUTICAL SUSPENSION IN A TWO-CHAMBER VIAL | PHARMACIA CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003105805-A1 | COMPOSITION FOR TREATMENT OF INFLAMMATORY DISORDERS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2003-12-24 | — | — | WO | disclosed |
| EP-1371362-A1 | Composition for treatment of inflammatory disorders | Universiteit Utrecht Holding B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297632-A1 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | FOLR1, FOLR2, ENPP2 | NR3C1 2000/4885FNTA 492/4885FNTB 1172/4885 |
| US-20220054417-A1 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES | FOLR1, FOLR2, ENPP2 | NR3C1 2000/4885FNTA 492/4885FNTB 1172/4885 |
| US-10406238-B2 | Ligand ionophore conjugates | EEA1, SLC7A1, LAMP2 | NR3C1 3181/4885FNTA 3051/4885FNTB 3266/4885 |
| US-20190298843-A1 | LIGAND IONOPHORE CONJUGATES | EEA1, SLC7A1, LAMP2 | NR3C1 3181/4885FNTA 3051/4885FNTB 3266/4885 |
| US-11185505-B2 | Delivery of agents to inflamed tissues using folate-targeted liposomes | FOLR1, FOLR2, ENPP2 | NR3C1 2000/4885FNTA 492/4885FNTB 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.